Circulatory support research
The Alfred Heart Failure and Transplant service remains committed to ongoing research to improve the quality of lives for patients living with VADs and advancing the management of these patients for the best clinical outcomes.
The Heart Failure and Transplant service at The Alfred cares for approximately twenty five to thirty patients with ventricular assist devices (VADs) per year.
From the first clinical research trial of the Australian designed VentrAssist VAD in 2002 we remain involved in research of the newest ventricular assist devices, most recently the HeartMate III as part of an international multi-center collaborative research trial.
Particular foci of research currently include ventricular assist device driveline infections, the haemodynamics of VADs with exercise, acute and long-term rehabilitation programmes for best physical outcomes post surgical implantation, quality of life of patients living with VADs and anticoagulation monitoring.
When Petra Brosch’s heart stopped beating during a routine run on Elwood beach, it was the beginning of a journey that would see The Alfred’s specialists drawing on the latest in cutting-edge medicine to save her life. The 35-year-old was suffering irreparable heart failure that would see her rely on life support, then an artificial heart and ultimatley organ transplant.